PubMed Health⌕ Search

Biomedical subjects

D Beauchamp

Publications and source records attributed to D Beauchamp.

80 records · Page 5Linked to original sources

Reduction of gentamicin nephrotoxicity by the concomitant administration of poly-l-aspartic acid and poly-l-asparagine in rats.

Williams and Hottendorf (1985) recently reported that poly-l-aspartic acid (pAsp) and poly-l-asparagine (pAsn) inhibit gentamicin (G) binding to brush border membrane vesicles in vitro and protect from G-induced nephrotoxicity in vivo. A model of infused rats was used to check for the early tissue alterations induced by G in animals receiving either G alone or the combination G + pAsp or G + pAsn. The cortical tissue was analysed 2 h or 2 days after the end of a 12 h infusion for signs of i) lysosomal phospholipidosis due to interference of G on phospholipids catabolism assessed by both biochemical (measurement of sphingomyelinase activity and of the total phospholipids content in renal cortex) and morphological analysis and ii) tubular regeneration and peritubular cells infiltration subsequent to focal necroses. While no reduction of G cortical levels was detected, significant changes in these parameters showed that G + pAsp and G + pAsn caused less phospholipidosis than G alone. Thus pAsp and pAsn decrease the severity of the early renal alterations induces by G.

Animals↗

Increased nephrotoxicity of gentamicin in pyelonephritic rats.

Multiple factors may increase the nephrotoxic potential of aminoglycosides. We studied gentamicin susceptibility of kidneys infected with E. coli. Several parameters of renal function, histological changes on light and electron microscopy, and drug levels in renal parenchyma were compared in pyelonephritic and normal rats treated with low doses (10 mg/kg/Q8 hr for 3 days), or high doses (60 mg/kg/day for 14 days), of gentamicin. A significant increase (P less than 0.01) in beta-galactosidase and protein excreted in urine over a period of 17 days associated with severe changes in diuresis and osmolality was noted in the infected treated rats (low doses) compared with normal, treated, infected or control animals. Histological modifications compatible with gentamicin nephrotoxicity were more persistent in the infected treated animals. A significant decrease in 14C inulin (P less than 0.01) and 3H-PAH clearance and secretion (P less than 0.02) was observed in the infected treated rats receiving high doses of antibiotics. Cellular necrosis and tubular desquamation also were more severe in this group. Gentamicin levels in the cortex and medulla of infected animals were significantly higher than in the normals (P less than 0.01) and might have been responsible for the increased toxicity noted in the pyelonephritic animals. Infected kidneys appeared to be more susceptible to the nephrotoxic potential of gentamicin.

Animals↗

Disturbed intrarenal distribution of gentamicin in experimental pyelonephritis due to Escherichia coli.

The intracortical, medullary, and papillary distribution of gentamicin was studied in normal and pyelonephritic rats. The animals were evaluated from 1 hr to 365 days after the end of therapy with either a single dose or two daily injections given every 12 hr for seven days. The serum levels of gentamicin at 1 hr were significantly (P less than 0.001) higher in the pyelonephritic rats than in the normal rats after one dose (26 vs. 12 microgram/ml) and 14 doses (25.7 vs. 8.8 microgram/ml). Peak concentrations or gentamicin in all parts of infected kidneys were significantly (P less than 0.001) higher than in normal kidneys. Gentamicin was still detectable at levels of 1.2 microgram/g in the cortex of one pyelonephritic animal one year after the end of therapy, when the levels of both serum creatinine (1.1 mg/100 ml) and blood urea nitrogen (30 mg/100 ml) were much higher than at seven days after the end of therapy (0.5 and 19 mg/100 ml, respectively).

Animals↗